Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 766 AL 780

Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide

Stocchi F, Torti M.

Drug Des Devel Ther. 2016 Feb 5;10:609-18. doi: 10.2147/DDDT.S77749. eCollection 2016.

Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease

Nowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D.

Mov Disord. 2016 May;31(5):725-33. doi: 10.1002/mds.26546. Epub 2016 Feb 26.

Antidromic Atrioventricular Reciprocating Tachycardia Using a Concealed Retrograde Conducting Left Lateral Accessory Pathway

Gonzalez JE, Zipse MM, Nguyen DT, Sauer WH.

Card Electrophysiol Clin. 2016 Mar;8(1):37-43. doi: 10.1016/j.ccep.2015.10.001. Epub 2016 Jan 11.

Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale

van der Heeden JF, Marinus J, Martinez-Martin P, van Hilten JJ.

Parkinsonism Relat Disord. 2016 Apr;25:39-44. doi: 10.1016/j.parkreldis.2016.02.016. Epub 2016 Feb 17.

Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions

Ramirez-Zamora A, Gee L, Boyd J, Biller J.

Expert Rev Neurother. 2016;16(4):389-99. doi: 10.1586/14737175.2016.1158103. Epub 2016 Mar 10.

Adaptive preconditioning in neurological diseases - therapeutic insights from proteostatic perturbations

Mollereau B, Rzechorzek NM, Roussel BD, Sedru M, Van den Brink DM, Bailly-Maitre B, Palladino F, Medinas DB, Domingos PM, Hunot S, Chandran S, Birman S, Baron T, Vivien D, Duarte CB, Ryoo HD, Steller H, Urano F, Chevet E, Kroemer G, Ciechanover A, Calabrese EJ, Kaufman RJ, Hetz C.

Brain Res. 2016 Oct 1;1648(Pt B):603-616. doi: 10.1016/j.brainres.2016.02.033. Epub 2016 Mar 2.

Olfactory impairment predicts cognitive decline in early Parkinson's disease

Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF.

Parkinsonism Relat Disord. 2016 Apr;25:45-51. doi: 10.1016/j.parkreldis.2016.02.013. Epub 2016 Feb 19.

The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review

Nakum S, Cavanna AE.

Parkinsonism Relat Disord. 2016 Apr;25:10-6. doi: 10.1016/j.parkreldis.2016.02.017. Epub 2016 Feb 18.

Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links

Moors T, Paciotti S, Chiasserini D, Calabresi P, Parnetti L, Beccari T, van de Berg WD.

Mov Disord. 2016 Jun;31(6):791-801. doi: 10.1002/mds.26562. Epub 2016 Feb 29.

[Aripiprazole, gambling disorder and compulsive sexuality]

Mété D, Dafreville C, Paitel V, Wind P.

Encephale. 2016 Jun;42(3):281-3. doi: 10.1016/j.encep.2016.01.003. Epub 2016 Feb 26.

ɑ-Synuclein strains and the variable pathologies of synucleinopathies

Peelaerts W, Baekelandt V.

J Neurochem. 2016 Oct;139 Suppl 1:256-274. doi: 10.1111/jnc.13595. Epub 2016 Mar 30.

Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy

Valera E, Monzio Compagnoni G, Masliah E.

Neuropathol Appl Neurobiol. 2016 Feb;42(1):95-106. doi: 10.1111/nan.12312.

4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery

Kim CH, Leblanc P, Kim KS.

Expert Opin Drug Discov. 2016;11(4):337-41. doi: 10.1517/17460441.2016.1154529. Epub 2016 Mar 7.

[Application of cell co-culture techniques in central nervous system diseases]

Yang S, He R, Zhang FY, Xue Q, Xu XY.

Yao Xue Xue Bao. 2016 Mar;51(3):338-46.

Targeting α-synuclein: Therapeutic options

Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, Bassil F, Meissner WG, Bezard E.

Mov Disord. 2016 Jun;31(6):882-8. doi: 10.1002/mds.26568. Epub 2016 Mar 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias